Paper Details

  1. Home
  2. Paper Details

Five-year treatment outcomes in the Ahmed Baerveldt comparison study.

Author: , BartonKeith, BudenzDonald L, BuysYvonne M, CostaVital P, FeuerWilliam J, GeddeSteven J, GodfreyDavid G, SchiffmanJoyce

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both the Ahmed FP7 Glaucoma Valve and the Baerveldt 101-350 Glaucoma Implant showed similar rates of surgical success at 5 years. However, the Baerveldt implant produced greater IOP reduction and a lower rate of glaucoma reoperation, but it was associated with twice as many failures due to safety issues.
Paper Details　
Original Abstract of the Article :
PURPOSE: To compare the 5-year outcomes of the Ahmed FP7 Glaucoma Valve (AGV) (New World Medical, Cucamonga, CA) and the Baerveldt 101-350 Glaucoma Implant (BGI) (Abbott Medical Optics, Abbott Park, IL) for the treatment of refractory glaucoma. DESIGN: Multicenter, randomized, controlled clinical t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25439606

データ提供：米国国立医学図書館（NLM）

Comparing Glaucoma Drainage Implants: Ahmed FP7 vs. Baerveldt 101-350

This research compares the long-term outcomes of two different glaucoma drainage implants (GDIs) used to treat refractory glaucoma, a condition that affects the eye's ability to drain fluid, leading to increased pressure and potential vision loss. The study investigates the effectiveness and safety of the Ahmed FP7 Glaucoma Valve (AGV) and the Baerveldt 101-350 Glaucoma Implant (BGI) over a five-year period.

Glaucoma Treatment: Navigating a Desert of Choices

The study presents valuable insights into the long-term performance of these two GDIs. While both implants demonstrated similar rates of surgical success at five years, the BGI produced greater intraocular pressure (IOP) reduction and a lower rate of glaucoma reoperation compared to the AGV. However, the BGI was associated with a higher rate of complications, including hypotony and implant explantation. This highlights the need for careful consideration of both efficacy and safety when choosing a GDI for treatment. It's like choosing the right camel for a desert expedition, weighing factors like speed, endurance, and carrying capacity against potential risks.

Balancing Efficacy and Safety in Glaucoma Treatment

The study underscores the importance of balancing efficacy and safety in glaucoma treatment. While the BGI may offer greater IOP reduction, the increased risk of complications should be carefully weighed against potential benefits. This emphasizes the need for individualized treatment plans and ongoing monitoring to ensure optimal outcomes for patients. It's like navigating a complex desert ecosystem, where understanding the delicate balance between resources and risks is crucial for survival.

Dr.Camel's Conclusion

This research offers a valuable comparison of two prominent GDIs, highlighting their strengths and limitations. It's like a desert map, revealing different routes to manage refractory glaucoma. The choice of implant depends on the patient's specific needs, and individualized care is paramount for navigating this challenging condition.

Date :
  1. Date Completed 2015-04-14
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

25439606

DOI: Digital Object Identifier

NIHMS625185

Related Literature

Article Analysis
・Effective treatment of glaucoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.